Growth Factors & Signaling

GHRP-6 (Growth Hormone Releasing Peptide-6)

For Research Use Only. Not for Human or Veterinary Use.

Overview

GHRP-6 is a synthetic hexapeptide ghrelin-receptor agonist and the prototypical growth-hormone-releasing peptide. First described in the 1980s, it was the peptide that established the GHRP class and remains a common historical benchmark. It is a strong GH secretagogue but also raises appetite and prolactin more than the newer, more selective peptides. It is a research compound.

Chemical Profile

PropertyValue
CAS number87616-84-0
ClassHexapeptide GHSR-1a agonist (first-generation GHRP)
Amino-acid sequenceH-His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
Molecular formulaC₄₆H₅₆N₁₂O₆
Molecular weight873.01 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
GHRP-6 at a glance
Class
Hexapeptide GHSR-1a agonist
First described
Bowers CY, 1980s
Research status
Extensive preclinical; limited clinical
Study routes
Subcutaneous, intranasal, oral
Half-life
≈ 30 min
Key feature
First-generation GHRP; historical benchmark

Mechanism of Action

GHRP-6 is the prototype GHSR-1a agonist against which later secretagogues are compared. It is a strong GH releaser, but it also engages ghrelin’s appetite pathway strongly and raises prolactin more than the selective peptides — the very properties that motivated the development of Ipamorelin and GHRP-2.

ComponentDetail
Primary targetGHSR-1a (ghrelin receptor)
G-protein couplingGαq/11 → PLC → IP₃ → Ca²⁺
GH releaseStrong
ProlactinSignificant (highest among these GHRPs)
AppetiteStrong (marked ghrelin-mimetic effect)

Pharmacology

ParameterValue
Half-life (t½)≈ 30 min
Bioavailability (SC)≈ 70–80%
Time to peak (Tmax)≈ 15–20 min
MetabolismProteolytic degradation
Route of administrationSubcutaneous, intranasal, oral (research)
EliminationRenal (peptide fragments)

Research Evidence

Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.

Study typeResearch focusReference
Foundational pharmacologyFirst peptide GH secretagogue with oral activityBowers CY, et al.
Animal / human GH studiesGH release and appetite effectsGHRP-6 literature
Cytoprotection researchGHSR signalling beyond GHGHRP-6 literature

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
First peptide GH secretagogue shown to be orally activefoundational studiesBowers CY et al.
Strong ghrelin-appetite signallinganimal modelsGHRP-6 literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 100–300 µg per injection, in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~2–4 weeks
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
Local tolerabilityMild injection-site reactions
Prolactin / cortisolProlactin rise more pronounced than other GHRPs
AppetiteStrong
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble
logP≈ −1.0 (hydrophilic)
pH (reconstituted)5.0–6.5
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

GHRP-6 is a C-terminally amidated hexapeptide made by Fmoc solid-phase synthesis, with D-tryptophan and D-phenylalanine as the D-configured residues; the two tryptophans need protection against oxidation at cleavage.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinRink amide resin (C-terminal amide)
Special residuesD-Trp, D-Phe (two Trp residues total)
CouplingHBTU / HOBt with DIPEA
CleavageTFA / TIPS / H₂O with scavengers
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. Two tryptophans make it more light-sensitive; confirm the D-residues.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, reversed-phase TFA/ACN gradientSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 873 Da
MALDI-TOFMass confirmation[M+H]⁺ ≈ 873 Da
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 873 Da). Two tryptophans make it more light-sensitive; confirm the D-residues.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: Two tryptophans make it more light-sensitive; confirm the D-residues.

Selected References

  • Bowers CY, et al. On the in-vitro and in-vivo activity of a new synthetic hexapeptide that acts on the pituitary to release growth hormone. (foundational GHRP literature).
  • GHSR-1a / ghrelin-receptor pharmacology reviews.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need GHRP-6 — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote